November 1, 2023 07:34 AM EDTUpdated 08:06 AM
R&D
Pharma

GSK touts Arexvy sales as it dom­i­nates US old­er adult RSV mar­ket, com­pa­ny cuts three ear­ly-stage as­sets

Ayisha Sharma

News Reporter

GSK’s RSV vac­cine Arexvy got off to a strong start in its first full quar­ter post-launch, the com­pa­ny re­vealed dur­ing its third-quar­ter earn­ings. It al­so …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times